HK1223031A1 - 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 - Google Patents

用於降低慢性肾病患者的心力衰竭的枸橼酸铁 Download PDF

Info

Publication number
HK1223031A1
HK1223031A1 HK16111332.6A HK16111332A HK1223031A1 HK 1223031 A1 HK1223031 A1 HK 1223031A1 HK 16111332 A HK16111332 A HK 16111332A HK 1223031 A1 HK1223031 A1 HK 1223031A1
Authority
HK
Hong Kong
Prior art keywords
increase
iron
reduce
kidney disease
chronic kidney
Prior art date
Application number
HK16111332.6A
Other languages
English (en)
Chinese (zh)
Inventor
恩裡克．普拉多蘇
恩里克．普拉多苏
羅恩．本圖爾
罗恩．本图尔
詹姆斯．
詹姆斯．F．奥利维耶罗三世
．奧利維耶羅三世
Original Assignee
凯克斯生物制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 凯克斯生物制药公司 filed Critical 凯克斯生物制药公司
Publication of HK1223031A1 publication Critical patent/HK1223031A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16111332.6A 2013-11-04 2014-11-03 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 HK1223031A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
HK1223031A1 true HK1223031A1 (zh) 2017-07-21

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111332.6A HK1223031A1 (zh) 2013-11-04 2014-11-03 用於降低慢性肾病患者的心力衰竭的枸橼酸铁

Country Status (15)

Country Link
US (3) US20160256486A1 (cg-RX-API-DMAC10.html)
EP (2) EP3065734A4 (cg-RX-API-DMAC10.html)
JP (3) JP2016535780A (cg-RX-API-DMAC10.html)
KR (1) KR102392441B1 (cg-RX-API-DMAC10.html)
CN (1) CN105873583A (cg-RX-API-DMAC10.html)
AU (1) AU2014341975A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016009901A8 (cg-RX-API-DMAC10.html)
CA (1) CA2928200A1 (cg-RX-API-DMAC10.html)
EA (1) EA201690926A1 (cg-RX-API-DMAC10.html)
HK (1) HK1223031A1 (cg-RX-API-DMAC10.html)
IL (1) IL245317A0 (cg-RX-API-DMAC10.html)
MX (1) MX2016005734A (cg-RX-API-DMAC10.html)
SG (1) SG11201603091QA (cg-RX-API-DMAC10.html)
TW (2) TWI744215B (cg-RX-API-DMAC10.html)
WO (1) WO2015066593A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (cg-RX-API-DMAC10.html) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
EP1978808B1 (en) 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
WO2015066593A1 (en) 2015-05-07
KR102392441B1 (ko) 2022-05-02
JP2019206562A (ja) 2019-12-05
MX2016005734A (es) 2016-11-08
US20250360167A1 (en) 2025-11-27
EP3747432A1 (en) 2020-12-09
JP2021073230A (ja) 2021-05-13
SG11201603091QA (en) 2016-05-30
TW201609088A (zh) 2016-03-16
EP3065734A4 (en) 2017-05-17
KR20160096597A (ko) 2016-08-16
US20160256486A1 (en) 2016-09-08
EA201690926A1 (ru) 2016-09-30
CA2928200A1 (en) 2015-05-07
BR112016009901A8 (pt) 2020-04-14
AU2014341975A1 (en) 2016-05-19
TW202203910A (zh) 2022-02-01
US20190307791A1 (en) 2019-10-10
JP2016535780A (ja) 2016-11-17
CN105873583A (zh) 2016-08-17
IL245317A0 (en) 2016-06-30
JP6828100B2 (ja) 2021-02-10
TWI744215B (zh) 2021-11-01
EP3065734A1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
WO2013192565A3 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
BR112016009901A8 (pt) uso de citrato férrico
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
MX2014011186A (es) Metodo para mejorar la eficiencia de las transfusiones de sangre.
MX2015013170A (es) Proteinas de union especificas duales dirigidas contra tnf alpha.
MX375476B (es) Composición farmacéutica que comprende empagliflozina, métodos para tratamiento y sus usos.
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
WO2014089209A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2014144280A8 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
Chavez et al. New insights into the regulation of vascular permeability
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
ES2543850R2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
WO2011157819A3 (en) Peptides as active agents to stabilize biological barriers
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject
JP2016511261A5 (cg-RX-API-DMAC10.html)
NZ725920A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
Shubina et al. Effect of chronic lead intoxication on formed elements morphology and some biochemical parameters of blood plasma of white rats
UA86387U (ru) Способ оценки эффективности лечения больных с артериальной гипертензией, объединенной с метаболическим синдромом
PH12015501764A1 (en) Food composition and its use against dehydration
MX355364B (es) Bebida para la reposición rápida de iones calcio en el torrente sanguíneo.
ZHOU et al. Synergistic effects of serum uric acid and cardiometabolic risk factors on early stage atherosclerosis: the cardiometabolic risk in Chinese (CRC) Study
WO2014075033A3 (en) Protein stabilizing factors